QR678 & QR678 Neo Hair Growth Formulations: A Cellular Toxicity & Animal Efficacy Study.
Kapoor. Rinky R; Shome. Debraj D; Vadera. Sapna S; Kumar. Vaibhav V; Ram. Male Shiva MS
Key Findings
- Both QR 678 and QR 678 Neo were non‑toxic to human keratinocyte and fibroblast cells in vitro.
- In mice, intradermal injections caused visible hair growth within a 0.25 cm radius of the injection site.
- The formulations were effective even in mice that had hair loss from chemotherapy, suggesting potential for secondary alopecia.
Practical Outcomes
- For biohackers, the data suggest these peptide‑based mixes could be safe and effective for hair regrowth, but only animal evidence exists so far. Until human trials are done, it’s not advisable to self‑administer; instead, watch for clinical studies or consider these compounds only under professional supervision if they become approved.
Summary
The study tested two new hair‑growth mixes (QR 678 and QR 678 Neo) that contain growth factors and copper‑tri‑peptide‑1. In lab dishes they didn’t hurt skin cells, and when injected under the skin of mice they grew new hair around the injection spot. The results are promising but have only been shown in mice, not people.
Abstract
Current treatment modalities are limited in their approach and success for hair loss. QR 678 & QR 678 Neo are new formulations, consisting of a combination of growth factors and peptides. This study demonstrates safety analysis of QR 678 & QR 678 Neo formulation, using in vitro cytotoxicity assay and in vivo animal efficacy. Factors including vascular endothelial growth factor, basic fibroblast growth factor, insulin-like growth factor-1, keratinocyte growth factor, and copper tripeptide 1 (QR 678) or their biomimetic peptides (QR678 Neo) were suspended in a sterile injectable vehicle. The 3-2,5-diphenyl tetrazolium bromide assay was used to explore the cytotoxic effects of each factor used in the compositions in human keratinocyte cell and human fibroblast cell assays. An in vivo analysis, wherein study animals were given intradermal QR 678 & QR 678 Neo injections, was conducted to assess whether the formulations produce hair growth. Also, hair follicle viability was checked by intradermal injection of the pharmaceutical compositions in secondary alopecia. In both formulations, a positive response was observed with respect to the number of mice exhibiting hair growth at the injection sites. The injections caused retention of hair in a 0.25-cm radius around the injection site. On cytotoxicity study, all the factors were found to be safe in human keratinocyte cell and human fibroblast cell assay. A positive response was demonstrated in animals on treatment with the chemotherapeutic agent. Intradermal injections of QR 678 & QR 678 Neo hair growth factor formulations are a safe and efficacious option for alopecia. Results seem encouraging enough to warrant a trial in humans with secondary alopecia, post cancer chemotherapy.
Study Information
pubmed
2020
2020-08-25T00:00:00.000Z
10.1097/gox.0000000000002843